guest ::
| Home > Publications database > Multiple mechanisms of MYCN dysregulation in Wilms tumour. |
| Home > Publications database > Multiple mechanisms of MYCN dysregulation in Wilms tumour. |
| Journal Article | DKFZ-2017-03816 |
; ; ; ; ; ; ; ; ; ; ; ; ; ;
2015
Impact Journals LLC
[S.l.]
This record in other databases: 
Please use a persistent id in citations: doi:10.18632/oncotarget.3377
Abstract: Genomic gain of the proto-oncogene transcription factor gene MYCN is associated with poor prognosis in several childhood cancers. Here we present a comprehensive copy number analysis of MYCN in Wilms tumour (WT), demonstrating that gain of this gene is associated with anaplasia and with poorer relapse-free and overall survival, independent of histology. Using whole exome and gene-specific sequencing, together with methylation and expression profiling, we show that MYCN is targeted by other mechanisms, including a recurrent somatic mutation, P44L, and specific DNA hypomethylation events associated with MYCN overexpression in tumours with high risk histologies. We describe parallel evolution of genomic copy number gain and point mutation of MYCN in the contralateral tumours of a remarkable bilateral case in which independent contralateral mutations of TP53 also evolve over time. We report a second bilateral case in which MYCN gain is a germline aberration. Our results suggest a significant role for MYCN dysregulation in the molecular biology of Wilms tumour. We conclude that MYCN gain is prognostically significant, and suggest that the novel P44L somatic variant is likely to be an activating mutation.
Keyword(s): Proto-Oncogene Proteins c-myc ; TP53 protein, human ; Tumor Suppressor Protein p53
; BIOSIS Previews ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
|
The record appears in these collections: |
